JP5816100B2 - 多能性細胞の分化 - Google Patents

多能性細胞の分化 Download PDF

Info

Publication number
JP5816100B2
JP5816100B2 JP2011552223A JP2011552223A JP5816100B2 JP 5816100 B2 JP5816100 B2 JP 5816100B2 JP 2011552223 A JP2011552223 A JP 2011552223A JP 2011552223 A JP2011552223 A JP 2011552223A JP 5816100 B2 JP5816100 B2 JP 5816100B2
Authority
JP
Japan
Prior art keywords
cells
differentiation
medium
cell
pluripotent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011552223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519005A (ja
JP2012519005A5 (enExample
Inventor
ディーピカ ラジェシュ，
ディーピカ ラジェシュ，
レイチェル ルイス，
レイチェル ルイス，
Original Assignee
セルラー ダイナミクス インターナショナル， インコーポレイテッド
セルラー ダイナミクス インターナショナル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルラー ダイナミクス インターナショナル， インコーポレイテッド, セルラー ダイナミクス インターナショナル， インコーポレイテッド filed Critical セルラー ダイナミクス インターナショナル， インコーポレイテッド
Publication of JP2012519005A publication Critical patent/JP2012519005A/ja
Publication of JP2012519005A5 publication Critical patent/JP2012519005A5/ja
Application granted granted Critical
Publication of JP5816100B2 publication Critical patent/JP5816100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011552223A 2009-02-27 2010-03-01 多能性細胞の分化 Active JP5816100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15630409P 2009-02-27 2009-02-27
US61/156,304 2009-02-27
PCT/US2010/025776 WO2010099539A1 (en) 2009-02-27 2010-03-01 Differentiation of pluripotent cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015158092A Division JP2015192681A (ja) 2009-02-27 2015-08-10 多能性細胞の分化

Publications (3)

Publication Number Publication Date
JP2012519005A JP2012519005A (ja) 2012-08-23
JP2012519005A5 JP2012519005A5 (enExample) 2013-04-18
JP5816100B2 true JP5816100B2 (ja) 2015-11-18

Family

ID=42097524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011552223A Active JP5816100B2 (ja) 2009-02-27 2010-03-01 多能性細胞の分化
JP2015158092A Pending JP2015192681A (ja) 2009-02-27 2015-08-10 多能性細胞の分化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015158092A Pending JP2015192681A (ja) 2009-02-27 2015-08-10 多能性細胞の分化

Country Status (9)

Country Link
US (2) US8372642B2 (enExample)
EP (1) EP2401364B1 (enExample)
JP (2) JP5816100B2 (enExample)
KR (1) KR101720961B1 (enExample)
CN (1) CN102388130B (enExample)
AU (1) AU2010217739B2 (enExample)
CA (1) CA2753679C (enExample)
IL (1) IL214818A (enExample)
WO (1) WO2010099539A1 (enExample)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170102040A (ko) 2006-04-14 2017-09-06 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
JP5804280B2 (ja) * 2009-09-08 2015-11-04 国立大学法人京都大学 多能性幹細胞からの肥満細胞の製造方法
CA2783437C (en) 2009-11-12 2020-08-04 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011068792A2 (en) * 2009-12-01 2011-06-09 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
CA3080368A1 (en) * 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
US9428735B2 (en) 2010-02-25 2016-08-30 The Johns Hopkins University Smooth muscle-like cells (SMLCs) dervided from human pluripotent stem cells
CA2802249A1 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
CN102985531B (zh) 2010-09-10 2019-04-23 国立大学法人东京大学 涉及由多能干细胞向血细胞分化的培养方法
WO2012103098A2 (en) * 2011-01-24 2012-08-02 Immunepath, Inc. Compositions and methods for treating hematological cytopenias
JP6148429B2 (ja) * 2011-01-31 2017-06-14 協和発酵バイオ株式会社 ヒト多能性幹細胞の培養方法
EP2673358B1 (en) * 2011-02-08 2019-01-09 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
CN102161980B (zh) * 2011-02-12 2013-07-31 浙江大学 用人间充质干细胞为滋养层培养诱导多能干细胞的方法
US9499789B2 (en) 2011-02-23 2016-11-22 Kyoto University Method for producing dendritic cells from pluripotent stem cells
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
GB201103600D0 (en) 2011-03-01 2011-04-13 Isis Innovation Dendritic cells
CA2831609C (en) * 2011-03-30 2019-06-11 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
MX349658B (es) * 2011-06-09 2017-08-08 Hoffmann La Roche Metodo para la diferenciacion de las celulas madre pluripotentes en celulas de lecho vascular.
HRP20171937T1 (hr) * 2011-09-29 2018-02-09 Cellsnap, Llc Pripravci za i postupci ispitivanja toksigenosti
EP2765187B1 (en) * 2011-10-03 2018-08-08 Nissan Chemical Industries, Ltd. Method for producing megakaryocytes and/or platelets from pluripotent stem cells
CN104053769A (zh) * 2011-11-21 2014-09-17 大学健康网络 造血祖细胞群体和富集其干细胞的方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CA2857545A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
KR20240019378A (ko) * 2011-12-01 2024-02-14 뉴욕 스템 셀 파운데이션, 인코포레이티드 유도 다능성 줄기 세포 또는 분화된 세포를 제조하기 위한 자동화 시스템
US10428309B2 (en) 2011-12-01 2019-10-01 New York Stem Cell Foundation, Inc. Systems and methods for producing stem cells and differentiated cells
WO2013130820A1 (en) * 2012-02-29 2013-09-06 The Johns Hopkins University Method for guiding the derivation of endothelial cells from human pluripotent stem cells employing two-dimensional, feeder-free differentiation
WO2013163171A1 (en) 2012-04-24 2013-10-31 Kaufman Dan S Method for developing natural killer cells from stem cells
GB201210857D0 (en) * 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CN105073980A (zh) * 2012-09-28 2015-11-18 公益财团法人先端医疗振兴财团 含有适合用于缺血性疾病治疗的细胞的细胞群体的体外增殖方法
SG11201502375QA (en) 2012-11-21 2015-05-28 Merz Pharma Gmbh & Co Kgaa Means and methods for determination of botulinum neurotoxin biological activity
WO2014100779A1 (en) * 2012-12-21 2014-06-26 Advanced Cell Technology, Inc. Methods ofr production of platelets from pluripotent stem cells and compositions thereof
HUE043785T2 (hu) 2013-03-13 2019-09-30 Wisconsin Alumni Res Found Módszerek és anyagok humán pluripotens õssejtek hematoendothelialis differenciálására meghatározott körülmények között
US9994825B2 (en) 2013-03-15 2018-06-12 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
US10731132B2 (en) 2013-03-15 2020-08-04 Amniotics Ab Methods and apparatuses for umbilical cord blood collection and isolation of cells
US9506037B2 (en) 2013-03-15 2016-11-29 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
AU2014232381A1 (en) * 2013-03-15 2015-10-29 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
US9822342B2 (en) 2013-05-14 2017-11-21 Kyoto University Method of efficiently inducing cardiomyocytes
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Ｎｋ細胞の調製方法
WO2014189144A1 (ja) * 2013-05-23 2014-11-27 国立大学法人京都大学 骨髄異形成症候群等の治療／予防薬のスクリーニング方法
EP3008169B1 (en) * 2013-06-10 2021-11-10 Academisch Ziekenhuis Leiden Differentiation and expansion of endothelial cells from pluripotent stem cells and the in vitro formation of vasculature like structures
SG11201510685UA (en) 2013-06-28 2016-01-28 Merz Pharma Gmbh & Co Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
WO2015050963A1 (en) * 2013-10-01 2015-04-09 Manfred Boehm Human ipsc-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings
WO2015119642A1 (en) * 2014-02-10 2015-08-13 The Johns Hopkins University Low oxygen tension enhances endothelial fate of human pluripotent stem cells
AU2015220915B2 (en) 2014-02-19 2020-09-17 Merz Pharma Gmbh & Co. Kgaa Gangliosides for standardizing and increasing the sensitivity of cells to Botulinum neurotoxins in in vitro test systems
US20170044500A1 (en) 2014-04-24 2017-02-16 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CN103937743B (zh) * 2014-04-27 2017-12-01 浙江大学 一种利用三维诱导系统获得造血干细胞的方法
MY195016A (en) 2014-08-04 2023-01-03 Nuevolution As Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
JP6772138B2 (ja) 2014-12-19 2020-10-21 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞内のＢｏＮＴ／Ｅの生物学的活性を決定するための手段及び方法
SG11201705695QA (en) 2015-01-16 2017-08-30 Agency Science Tech & Res Differentiation of macrophages from pluripotent stem cells
WO2016118824A1 (en) 2015-01-22 2016-07-28 Regenerative Medical Solutions, Inc. Markers for differentiation of stem cells into differentiated cell populations
JP6800859B2 (ja) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
TWI704156B (zh) 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法
EP3298131B1 (en) * 2015-05-20 2023-04-26 The Regents of The University of California Method for generating human dendritic cells for immunotherapy
EP4026563B1 (en) * 2015-06-18 2025-10-29 Yeda Research and Development Co. Ltd Conditioning protocols and use of same for tissue regeneration
ES2971677T3 (es) * 2015-09-08 2024-06-06 Sumitomo Pharma Co Ltd Método para la producción de tejido retiniano
DK3365435T3 (da) * 2015-10-20 2021-04-06 Fujifilm Cellular Dynamics Inc Produktion af hæmatopoietiske prækursorceller med multi-afstamning med genetisk programmering
AU2016343682A1 (en) 2015-10-30 2018-06-14 The Regents Of The University Of California Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
JP7534070B2 (ja) 2015-11-04 2024-08-14 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
CN115806940A (zh) 2015-11-04 2023-03-17 菲特治疗公司 多能细胞的基因组工程改造
CN105296428A (zh) * 2015-12-03 2016-02-03 广州医科大学附属第三医院 一种提高诱导多能干细胞的体外分化造血效率的方法
US20190002834A1 (en) * 2015-12-29 2019-01-03 Kuraray Co., Ltd. Method for preparing population of stem cell spheroids
GB201601503D0 (en) 2016-01-27 2016-03-09 Isis Innovation Dendritic cells
DK3460042T3 (da) 2016-05-18 2024-03-11 Univ Keio Celledyrkningsmedium til dyrkning af et organoid, dyrkningsfremgnagsmåde og organoid
US20190161726A1 (en) * 2016-07-29 2019-05-30 Daikin Industries, Ltd. Differentiated cell production method and culture bag used therefor
JP6963555B2 (ja) * 2016-09-02 2021-11-10 タカラバイオ株式会社 多能性幹細胞からミクログリアを得る方法
US11525119B2 (en) 2016-09-06 2022-12-13 The Children's Medical Center Corporation Immune cells derived from induced pluripotent stem cell
ES3009605T3 (en) 2016-10-05 2025-03-27 Fujifilm Cellular Dynamics Inc Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
AU2017340644B2 (en) * 2016-10-05 2024-05-09 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to HLA homozygous immune cells
CN106479968A (zh) * 2016-10-11 2017-03-08 海南博鳌龄迈迪精准医学研究院有限公司 脐带间充质干细胞的培养方法
WO2018073615A1 (en) 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
CN106754684A (zh) * 2017-01-05 2017-05-31 厚朴生物科技（苏州）有限公司 一种睾丸间质干细胞分离培养分化方法
EP3587560A4 (en) 2017-01-27 2020-12-16 Kaneka Corporation Endodermal cell mass, and method for producing any one of three primary germ layer cell mass from pluripotent cells
US11932876B2 (en) * 2017-02-03 2024-03-19 Cornell University Stable three-dimensional blood vessels and methods for forming the same
JP7134998B2 (ja) * 2017-03-21 2022-09-12 エタブリスモン フランセ ドュ サン 造血移植片の改善方法
BR112019021745A2 (pt) 2017-04-18 2020-05-05 Fujifilm Cellular Dynamics Inc células efetoras imunológicas antígeno-específicas
EP3399027A1 (en) 2017-05-04 2018-11-07 Medizinische Hochschule Hannover Stem-cell derived myeloid cells, generation and use thereof
CN107083367B (zh) * 2017-07-03 2020-07-14 广州润虹医药科技股份有限公司 培养基及其用途与由尿液细胞制备间充质干细胞的方法
KR102051470B1 (ko) * 2017-12-11 2019-12-03 대한민국 전분화능 줄기세포를 이용한 면역세포 분화
US11365390B2 (en) 2017-12-19 2022-06-21 Xcell Biosciences, Inc. Methods of modulating cell phenotype by way of regulating the gaseous environment
CN108048390B (zh) * 2017-12-21 2021-04-27 清华大学 一种制备血管内皮细胞的方法及其专用试剂盒
CN108588024B (zh) * 2017-12-29 2020-04-21 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 诱导多能干细胞分化成造血干细胞的培养基及方法
KR102592176B1 (ko) * 2018-01-05 2023-10-20 플레이틀렛 바이오제네시스, 인크. 거핵구 생성을 위한 조성물 및 방법
NZ766453A (en) 2018-02-01 2022-02-25 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
JP2021529770A (ja) 2018-06-29 2021-11-04 プレートレット バイオジェネシス， インコーポレイテッド 薬物送達のための組成物およびその使用方法
CN112739816B (zh) 2018-09-19 2025-09-12 富士胶片细胞动力公司 用于激活和扩增嵌合抗原受体-修饰的免疫细胞的蛋白l
CN109266618B (zh) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 能够靶向肿瘤细胞的巨噬细胞及其制备方法
WO2020086889A1 (en) * 2018-10-24 2020-04-30 Hebecell Corporation Methods and systems for manufacturing hematopoietic lineage cells
KR102111441B1 (ko) * 2018-11-12 2020-05-15 대한민국 전분화능 줄기세포 유래 대식세포를 기반으로 하는 감염질환 치료용 약물 스크리닝 방법
JP7446242B2 (ja) * 2018-12-20 2024-03-08 住友化学株式会社 胚型赤芽球を含む細胞集団及びその製造方法、細胞培養組成物並びに化合物試験法
JP7634938B2 (ja) * 2019-02-21 2025-02-25 ピービーエス バイオテック インコーポレイテッド バイオリアクターにおける治療細胞の膨張および分化のためのシステムおよび方法
CN111206017B (zh) * 2019-04-30 2022-02-18 浙江大学 一种干细胞无血清培养基及其应用
US20220251516A1 (en) * 2019-06-14 2022-08-11 FUJIFILM Cellular Dynamics, Inc. Methods for the production of multiple lineages from induced pluripotent stem cells using charged surfaces
EP3986358A4 (en) 2019-06-20 2023-06-21 Amniotics AB DEVICE FOR FILTERING FRUIT WATER
EP4234019A3 (en) 2019-10-18 2023-09-13 Amniotics AB Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
WO2021096218A1 (ko) * 2019-11-13 2021-05-20 연세대학교 산학협력단 혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법
CN110938584B (zh) * 2019-11-25 2021-12-03 广州赛莱拉干细胞科技股份有限公司 一种人胚胎干细胞向内皮细胞诱导分化的方法
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
EP4110900A4 (en) * 2020-02-28 2024-04-24 Purdue Research Foundation GENERATING AORTA-GONAD-MESONEPHROS-LIKE HEMATOPOETIC CELLS FROM HUMAN PLURIPOTENT STEM CELLS UNDER A DEFINED STATE
US12220445B2 (en) 2020-03-09 2025-02-11 Amprion, Inc. Inert matrices for qualitative and semi-quantitative seed amplification assays
CN111440760B (zh) * 2020-03-09 2022-09-23 浙江大学 一种人多能干细胞高效分化得到内皮祖细胞的方法
US11547726B2 (en) * 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
CN115698335A (zh) 2020-05-22 2023-02-03 因斯特罗公司 使用机器学习模型预测疾病结果
EP4170020A4 (en) 2020-06-17 2025-01-22 Kyoto University IMMUNOCOMPETENT CELLS WITH CHIMERIC ANTIGEN RECEPTOR EXPRESSION
JP2023536125A (ja) * 2020-07-27 2023-08-23 ステムセル テクノロジーズ カナダ インコーポレイテッド 造血細胞を分化させるシステム及び方法
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
MX2023006395A (es) 2020-12-03 2023-06-15 Century Therapeutics Inc Celulas dise?adas geneticamente y usos de estas.
CN112608895B (zh) * 2020-12-18 2024-02-27 深圳市济因生物科技有限公司 一种人多能干细胞分化的自然杀伤细胞及其制备方法与应用
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2022216857A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
WO2022216514A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
AU2022255166A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
JP2024516992A (ja) 2021-05-05 2024-04-18 フジフィルム セルラー ダイナミクス，インコーポレイテッド Ｉｐｓｃ由来ミクログリアのための方法及び組成物
CA3231278A1 (en) 2021-09-10 2023-03-16 Deepika Rajesh Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
CA3232289A1 (en) * 2021-09-13 2023-03-16 Amprion, Inc. Inert matrices for qualitative and semi-quantitative seed amplification assays
TW202330592A (zh) 2021-12-15 2023-08-01 美商Ｙ單克隆抗體製藥有限公司 具有經減少之多聚化(MULTIMERISATION)的scFv及抗體
AU2022423987A1 (en) 2021-12-29 2024-07-11 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
AU2023223404A1 (en) 2022-02-22 2024-08-29 Juno Therapeutics, Inc. Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
US20250345425A1 (en) 2022-05-04 2025-11-13 Century Therapeutics, Inc. Cells engineered with an hla-e and hla-g transgene
EP4536814A1 (en) 2022-06-08 2025-04-16 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
JP2025522360A (ja) 2022-06-08 2025-07-15 センチュリー セラピューティクス，インコーポレイテッド Ｃｄ１６変異体およびｎｋｇ２ｄを発現する遺伝子操作した細胞ならびにその使用
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
CN120435498A (zh) 2022-11-10 2025-08-05 世纪治疗股份有限公司 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途
US20240269189A1 (en) 2022-12-19 2024-08-15 FUJIFILM Holdings America Corporation Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
CN120958116A (zh) * 2023-02-16 2025-11-14 辛泰克斯生物公司 用于将细胞编程为造血谱系的系统及其方法
CN116426472A (zh) * 2023-06-08 2023-07-14 呈诺再生医学科技(北京)有限公司 一种促进造血干细胞或造血祖细胞分化为红细胞的诱导分化体系及其应用
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
EP0924983A4 (en) 1996-07-19 1999-08-25 Gunnar Aberg S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
WO2000057913A1 (en) 1999-03-25 2000-10-05 Welfide Corporation Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
WO2000078351A1 (en) 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
EP1367899A4 (en) * 2001-02-14 2004-07-28 Leo T Furcht TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS
CA2469483C (en) * 2001-12-07 2017-07-25 Geron Corporation Hematopoietic cells from human embryonic stem cells
WO2003055989A2 (en) * 2001-12-21 2003-07-10 Mount Sinai Hospital Cellular compositions and methods of making and using them
ES2298497T3 (es) * 2002-01-23 2008-05-16 Bayer Pharmaceuticals Corporation Inhibidores de quinasa rho.
US6664266B2 (en) * 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003234186B2 (en) 2002-04-22 2009-01-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C Gamma for pain management
US7723106B2 (en) * 2004-07-29 2010-05-25 Food Industry Research & Development Institute Stroma-free, serum-free, and chemically defined medium and method for ex vivo mononuclear cell expansion using the same
JP2007527917A (ja) 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
US7452718B2 (en) * 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
WO2006029197A1 (en) * 2004-09-08 2006-03-16 Wisconsin Alumni Research Foundation Medium and culture of embryonic stem cells
KR20070073932A (ko) 2004-11-01 2007-07-10 위스콘신 얼럼나이 리서어치 화운데이션 줄기 세포 유래 혈소판
US20070077654A1 (en) * 2004-11-01 2007-04-05 Thomson James A Platelets from stem cells
JP4964121B2 (ja) * 2005-02-23 2012-06-27 財団法人先端医療振興財団 血管内皮前駆細胞の生体外増幅方法
ATE446509T1 (de) * 2005-11-28 2009-11-15 Choongwae Pharma Corp Serumfreie expansion von zellen in kultur
JP2008099662A (ja) * 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
WO2008056779A1 (fr) * 2006-11-09 2008-05-15 Japan As Represented By The President Of International Medical Center Of Japan Procédé destiné à la culture et au passage d'une cellule souche embryonnaire de primate, et procédé destiné à induire la différenciation de la cellule souche embryonnaire
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
SG192449A1 (en) 2008-03-27 2013-08-30 Geron Corp Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
US8513012B2 (en) * 2008-05-02 2013-08-20 Cellular Dynamics International, Inc. Method for production of mast cells from stem cells
WO2010035136A2 (en) * 2008-09-25 2010-04-01 Uti Limited Partnership Expansion of embryonic stem cells

Also Published As

Publication number Publication date
US20130210141A1 (en) 2013-08-15
IL214818A0 (en) 2011-11-30
JP2015192681A (ja) 2015-11-05
AU2010217739A1 (en) 2011-09-08
CA2753679C (en) 2021-03-02
CN102388130B (zh) 2014-08-27
US10100282B2 (en) 2018-10-16
IL214818A (en) 2014-07-31
EP2401364A1 (en) 2012-01-04
CA2753679A1 (en) 2010-09-02
CN102388130A (zh) 2012-03-21
KR20110122858A (ko) 2011-11-11
EP2401364B1 (en) 2015-04-22
US8372642B2 (en) 2013-02-12
WO2010099539A1 (en) 2010-09-02
US20100279403A1 (en) 2010-11-04
JP2012519005A (ja) 2012-08-23
AU2010217739B2 (en) 2015-09-03
KR101720961B1 (ko) 2017-03-29

Similar Documents

Publication Publication Date Title
JP5816100B2 (ja) 多能性細胞の分化
JP2012519005A5 (enExample)
AU2020264375B2 (en) Method for developing natural killer cells from stem cells
JP6189581B2 (ja) 幹細胞の分化のための方法および組成物
US20200157503A1 (en) Hemangio colony forming cells and non-engrafting hemangio cells
CN117264888A (zh) 一种制备造血干细胞和祖细胞的方法
HK40017506A (en) Method for developing natural killer cells from stem cells

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150925

R150 Certificate of patent or registration of utility model

Ref document number: 5816100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250